Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Liver Transplantation | 27 | 2018 | 93 | 4.680 |
Why?
|
Liver | 11 | 2019 | 144 | 2.020 |
Why?
|
Kidney Transplantation | 10 | 2021 | 120 | 1.910 |
Why?
|
Living Donors | 10 | 2011 | 15 | 1.430 |
Why?
|
Portal Vein | 7 | 2018 | 43 | 1.320 |
Why?
|
Hepatectomy | 7 | 2018 | 58 | 1.230 |
Why?
|
Carcinoma, Hepatocellular | 6 | 2021 | 26 | 1.200 |
Why?
|
Liver Neoplasms | 6 | 2021 | 93 | 1.120 |
Why?
|
Liver Failure, Acute | 4 | 2018 | 5 | 0.780 |
Why?
|
Pancreatitis | 1 | 2021 | 20 | 0.770 |
Why?
|
Gallstones | 1 | 2021 | 9 | 0.770 |
Why?
|
Hepatomegaly | 1 | 2018 | 7 | 0.630 |
Why?
|
Humans | 53 | 2022 | 25692 | 0.620 |
Why?
|
Kidney Failure, Chronic | 7 | 2020 | 148 | 0.560 |
Why?
|
Liver Regeneration | 4 | 2017 | 24 | 0.550 |
Why?
|
Tissue Donors | 2 | 2009 | 61 | 0.520 |
Why?
|
Middle Aged | 28 | 2020 | 8403 | 0.500 |
Why?
|
Retrospective Studies | 15 | 2022 | 3220 | 0.480 |
Why?
|
Swine | 7 | 2018 | 71 | 0.460 |
Why?
|
Male | 34 | 2021 | 13917 | 0.440 |
Why?
|
Bile Ducts | 2 | 2011 | 11 | 0.430 |
Why?
|
BK Virus | 1 | 2013 | 11 | 0.420 |
Why?
|
Constriction, Pathologic | 2 | 2019 | 31 | 0.420 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2013 | 16 | 0.420 |
Why?
|
Organ Preservation | 2 | 2011 | 6 | 0.410 |
Why?
|
Perfusion | 2 | 2011 | 12 | 0.410 |
Why?
|
Kidney Neoplasms | 1 | 2013 | 70 | 0.400 |
Why?
|
Hypertension, Malignant | 1 | 2012 | 1 | 0.390 |
Why?
|
Protein S Deficiency | 1 | 2011 | 2 | 0.390 |
Why?
|
Female | 27 | 2021 | 14273 | 0.390 |
Why?
|
Galactosyltransferases | 2 | 2013 | 2 | 0.380 |
Why?
|
Hypercholesterolemia | 1 | 2011 | 26 | 0.380 |
Why?
|
Arteriovenous Shunt, Surgical | 2 | 2022 | 23 | 0.370 |
Why?
|
Mesentery | 1 | 2011 | 5 | 0.370 |
Why?
|
Carcinoid Tumor | 1 | 2011 | 5 | 0.370 |
Why?
|
Ligation | 4 | 2018 | 33 | 0.370 |
Why?
|
Peritoneal Neoplasms | 1 | 2011 | 7 | 0.370 |
Why?
|
Kidney | 4 | 2021 | 155 | 0.360 |
Why?
|
Animals | 11 | 2021 | 3510 | 0.350 |
Why?
|
Intestines | 1 | 2011 | 88 | 0.350 |
Why?
|
Decision Support Techniques | 1 | 2010 | 46 | 0.350 |
Why?
|
Endothelial Cells | 1 | 2010 | 57 | 0.340 |
Why?
|
Postoperative Complications | 9 | 2022 | 827 | 0.340 |
Why?
|
Adrenal Cortex Neoplasms | 2 | 2020 | 12 | 0.340 |
Why?
|
Adrenocortical Carcinoma | 2 | 2020 | 14 | 0.330 |
Why?
|
Food Hypersensitivity | 1 | 2009 | 40 | 0.320 |
Why?
|
Treatment Outcome | 15 | 2022 | 3231 | 0.310 |
Why?
|
Bile Duct Neoplasms | 2 | 2005 | 5 | 0.310 |
Why?
|
Hepatopulmonary Syndrome | 1 | 2008 | 1 | 0.300 |
Why?
|
Hepatitis C | 2 | 2008 | 44 | 0.300 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 45 | 0.300 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2008 | 25 | 0.300 |
Why?
|
Informed Consent | 2 | 2005 | 21 | 0.290 |
Why?
|
Tissue and Organ Harvesting | 3 | 2004 | 19 | 0.290 |
Why?
|
Biliary Tract Diseases | 2 | 2019 | 6 | 0.270 |
Why?
|
Tissue and Organ Procurement | 2 | 2003 | 24 | 0.270 |
Why?
|
Coccidioides | 1 | 2006 | 1 | 0.260 |
Why?
|
Coccidioidomycosis | 1 | 2006 | 6 | 0.260 |
Why?
|
Registries | 1 | 2007 | 170 | 0.260 |
Why?
|
Transplantation, Heterologous | 2 | 2016 | 17 | 0.250 |
Why?
|
Liver Diseases | 2 | 2017 | 32 | 0.250 |
Why?
|
Directed Tissue Donation | 1 | 2005 | 1 | 0.240 |
Why?
|
Donor Selection | 1 | 2005 | 1 | 0.240 |
Why?
|
Neoplasm Staging | 3 | 2018 | 315 | 0.240 |
Why?
|
Physician-Patient Relations | 1 | 2005 | 37 | 0.230 |
Why?
|
Survival Rate | 5 | 2020 | 308 | 0.230 |
Why?
|
Adult | 13 | 2020 | 7336 | 0.230 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 2 | 2021 | 9 | 0.230 |
Why?
|
Hepatitis B, Chronic | 1 | 2003 | 4 | 0.220 |
Why?
|
Postoperative Hemorrhage | 2 | 2014 | 24 | 0.220 |
Why?
|
Biliary Tract Surgical Procedures | 2 | 2019 | 4 | 0.220 |
Why?
|
Communication | 1 | 2005 | 119 | 0.220 |
Why?
|
Incidence | 3 | 2021 | 731 | 0.220 |
Why?
|
Venous Thrombosis | 2 | 2019 | 42 | 0.210 |
Why?
|
Liver Failure | 2 | 2018 | 10 | 0.200 |
Why?
|
Time Factors | 6 | 2022 | 1336 | 0.200 |
Why?
|
Aneurysm | 1 | 2022 | 10 | 0.200 |
Why?
|
Gastroparesis | 1 | 2022 | 2 | 0.200 |
Why?
|
Arteriovenous Fistula | 1 | 2022 | 12 | 0.200 |
Why?
|
Pancreaticoduodenectomy | 1 | 2022 | 15 | 0.200 |
Why?
|
Urogenital Abnormalities | 1 | 2021 | 7 | 0.190 |
Why?
|
Hospitals, University | 1 | 2001 | 25 | 0.190 |
Why?
|
Infertility, Female | 1 | 2021 | 11 | 0.190 |
Why?
|
Specialization | 1 | 2001 | 16 | 0.190 |
Why?
|
Cholecystectomy | 1 | 2021 | 19 | 0.190 |
Why?
|
Organ Transplantation | 1 | 2021 | 22 | 0.190 |
Why?
|
Immunoglobulin G | 2 | 2013 | 92 | 0.190 |
Why?
|
Follow-Up Studies | 5 | 2020 | 1689 | 0.190 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 169 | 0.190 |
Why?
|
Organ Size | 2 | 2018 | 103 | 0.190 |
Why?
|
Random Allocation | 2 | 2018 | 116 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2021 | 24 | 0.190 |
Why?
|
Transplant Recipients | 1 | 2021 | 20 | 0.190 |
Why?
|
Bone Marrow Transplantation | 2 | 2013 | 22 | 0.190 |
Why?
|
Pancreas | 1 | 2021 | 29 | 0.190 |
Why?
|
Pancreatic Neoplasms | 2 | 2019 | 89 | 0.180 |
Why?
|
Renal Dialysis | 4 | 2022 | 115 | 0.180 |
Why?
|
Surgical Instruments | 1 | 2020 | 18 | 0.180 |
Why?
|
Prognosis | 4 | 2020 | 739 | 0.180 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 92 | 0.180 |
Why?
|
Ultrasonography | 3 | 2018 | 235 | 0.180 |
Why?
|
Hepatic Veins | 2 | 2018 | 9 | 0.170 |
Why?
|
Health Care Costs | 1 | 2020 | 75 | 0.170 |
Why?
|
Graft Survival | 7 | 2016 | 92 | 0.170 |
Why?
|
Margins of Excision | 1 | 2020 | 20 | 0.170 |
Why?
|
Adrenalectomy | 1 | 2019 | 4 | 0.170 |
Why?
|
Jejunostomy | 1 | 2019 | 8 | 0.170 |
Why?
|
Suture Techniques | 1 | 2020 | 136 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 69 | 0.170 |
Why?
|
Hospitalization | 1 | 2021 | 292 | 0.160 |
Why?
|
Patient Compliance | 1 | 2020 | 148 | 0.160 |
Why?
|
Abdominal Neoplasms | 1 | 2019 | 14 | 0.160 |
Why?
|
Heat Stroke | 1 | 2018 | 1 | 0.160 |
Why?
|
Intestinal Neoplasms | 1 | 2018 | 10 | 0.160 |
Why?
|
Digestive System Surgical Procedures | 1 | 2018 | 22 | 0.150 |
Why?
|
Child, Preschool | 2 | 2013 | 640 | 0.150 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 30 | 0.150 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 32 | 0.150 |
Why?
|
Papio | 3 | 2016 | 6 | 0.150 |
Why?
|
Pulmonary Embolism | 1 | 2019 | 55 | 0.150 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 53 | 0.150 |
Why?
|
Neovascularization, Physiologic | 1 | 2017 | 19 | 0.140 |
Why?
|
Hypertrophy | 1 | 2017 | 23 | 0.140 |
Why?
|
Vascular Patency | 4 | 2022 | 17 | 0.140 |
Why?
|
Aged | 10 | 2020 | 8501 | 0.130 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 97 | 0.130 |
Why?
|
Liver Cirrhosis | 2 | 2014 | 37 | 0.130 |
Why?
|
Disease Models, Animal | 1 | 2018 | 584 | 0.130 |
Why?
|
Graft Occlusion, Vascular | 2 | 2022 | 19 | 0.130 |
Why?
|
Liver Function Tests | 2 | 2015 | 19 | 0.130 |
Why?
|
Tobacco Use Disorder | 1 | 2015 | 16 | 0.120 |
Why?
|
Jaundice, Obstructive | 1 | 2015 | 1 | 0.120 |
Why?
|
Biopsy | 2 | 2013 | 199 | 0.120 |
Why?
|
Cysts | 1 | 2015 | 16 | 0.120 |
Why?
|
Graft Rejection | 4 | 2020 | 63 | 0.120 |
Why?
|
Antibodies, Heterophile | 1 | 2013 | 1 | 0.110 |
Why?
|
Papio hamadryas | 1 | 2013 | 1 | 0.110 |
Why?
|
Swine, Miniature | 1 | 2013 | 5 | 0.110 |
Why?
|
Heterografts | 1 | 2013 | 12 | 0.110 |
Why?
|
Heart-Assist Devices | 1 | 2014 | 16 | 0.110 |
Why?
|
Heart Transplantation | 1 | 2014 | 29 | 0.110 |
Why?
|
Bilirubin | 2 | 2011 | 11 | 0.110 |
Why?
|
Creatinine | 1 | 2013 | 47 | 0.110 |
Why?
|
Hypoxia | 2 | 2017 | 35 | 0.110 |
Why?
|
Hematoma | 1 | 2013 | 18 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 3 | 2015 | 1084 | 0.110 |
Why?
|
Ureterostomy | 1 | 2012 | 1 | 0.100 |
Why?
|
Polytetrafluoroethylene | 2 | 2011 | 5 | 0.100 |
Why?
|
Cystostomy | 1 | 2012 | 5 | 0.100 |
Why?
|
Blood Vessel Prosthesis | 2 | 2011 | 12 | 0.100 |
Why?
|
Databases, Factual | 3 | 2019 | 329 | 0.100 |
Why?
|
Ureter | 1 | 2012 | 26 | 0.100 |
Why?
|
Hepatic Encephalopathy | 1 | 2012 | 3 | 0.100 |
Why?
|
Protein S | 1 | 2011 | 1 | 0.100 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 91 | 0.100 |
Why?
|
Patient Selection | 3 | 2015 | 170 | 0.100 |
Why?
|
Intracranial Pressure | 1 | 2012 | 12 | 0.100 |
Why?
|
Warm Ischemia | 1 | 2011 | 2 | 0.100 |
Why?
|
Bile | 1 | 2011 | 5 | 0.100 |
Why?
|
Intracranial Hypertension | 1 | 2012 | 14 | 0.100 |
Why?
|
Monitoring, Intraoperative | 1 | 2012 | 33 | 0.100 |
Why?
|
Alkaline Phosphatase | 1 | 2011 | 19 | 0.100 |
Why?
|
Hepatitis, Autoimmune | 1 | 2011 | 5 | 0.100 |
Why?
|
Hemodynamics | 1 | 2011 | 57 | 0.100 |
Why?
|
Energy Metabolism | 1 | 2011 | 47 | 0.090 |
Why?
|
Oxygen | 1 | 2011 | 74 | 0.090 |
Why?
|
Endoscopy, Digestive System | 1 | 2011 | 8 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 698 | 0.090 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2011 | 16 | 0.090 |
Why?
|
Waiting Lists | 2 | 2014 | 16 | 0.090 |
Why?
|
Intestinal Obstruction | 1 | 2011 | 11 | 0.090 |
Why?
|
Complement C3a | 1 | 2010 | 1 | 0.090 |
Why?
|
End Stage Liver Disease | 1 | 2010 | 13 | 0.090 |
Why?
|
Transplantation, Autologous | 1 | 2011 | 151 | 0.090 |
Why?
|
Complement Activation | 1 | 2010 | 10 | 0.090 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2010 | 16 | 0.090 |
Why?
|
Immunoglobulin M | 1 | 2010 | 14 | 0.090 |
Why?
|
Tissue Engineering | 1 | 2010 | 30 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2010 | 157 | 0.090 |
Why?
|
Risk Factors | 3 | 2022 | 2224 | 0.080 |
Why?
|
Young Adult | 2 | 2020 | 1855 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2009 | 51 | 0.080 |
Why?
|
Anaphylaxis | 1 | 2009 | 9 | 0.080 |
Why?
|
Survival Analysis | 3 | 2018 | 246 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2010 | 198 | 0.080 |
Why?
|
Nephrectomy | 1 | 2009 | 35 | 0.080 |
Why?
|
Hemophilia A | 1 | 2008 | 41 | 0.080 |
Why?
|
Transplantation Chimera | 1 | 2008 | 1 | 0.070 |
Why?
|
Transplantation Tolerance | 1 | 2008 | 2 | 0.070 |
Why?
|
Cadaver | 1 | 2009 | 349 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2019 | 299 | 0.070 |
Why?
|
Reoperation | 1 | 2012 | 818 | 0.070 |
Why?
|
Colonoscopy | 1 | 2008 | 62 | 0.070 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 124 | 0.070 |
Why?
|
Rats, Wistar | 2 | 2017 | 49 | 0.070 |
Why?
|
New England | 1 | 2006 | 3 | 0.070 |
Why?
|
Cholangitis, Sclerosing | 1 | 2006 | 3 | 0.060 |
Why?
|
Hepatoblastoma | 1 | 2005 | 1 | 0.060 |
Why?
|
Cholangiocarcinoma | 1 | 2005 | 3 | 0.060 |
Why?
|
Blood Coagulation Factors | 2 | 2016 | 19 | 0.060 |
Why?
|
Hemangioendothelioma, Epithelioid | 1 | 2005 | 5 | 0.060 |
Why?
|
Cystic Duct | 1 | 2005 | 1 | 0.060 |
Why?
|
Coercion | 1 | 2005 | 5 | 0.060 |
Why?
|
Cholestasis | 1 | 2005 | 10 | 0.060 |
Why?
|
Social Values | 1 | 2005 | 9 | 0.060 |
Why?
|
Postoperative Period | 2 | 2019 | 292 | 0.060 |
Why?
|
Interview, Psychological | 1 | 2005 | 41 | 0.060 |
Why?
|
Medical Oncology | 1 | 2005 | 35 | 0.060 |
Why?
|
Liver Circulation | 2 | 2017 | 6 | 0.060 |
Why?
|
Animals, Genetically Modified | 2 | 2014 | 18 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 281 | 0.060 |
Why?
|
Contrast Media | 1 | 2004 | 68 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2005 | 86 | 0.060 |
Why?
|
Adenoma | 1 | 2005 | 56 | 0.060 |
Why?
|
Anastomosis, Surgical | 2 | 2019 | 30 | 0.050 |
Why?
|
United States | 2 | 2020 | 1943 | 0.050 |
Why?
|
Decision Making | 1 | 2005 | 203 | 0.050 |
Why?
|
Pancreatic Fistula | 1 | 2022 | 3 | 0.050 |
Why?
|
Strategic Planning | 1 | 2021 | 7 | 0.050 |
Why?
|
Steroids | 1 | 2022 | 23 | 0.050 |
Why?
|
Rats | 2 | 2016 | 649 | 0.050 |
Why?
|
Uterus | 1 | 2021 | 14 | 0.050 |
Why?
|
Hysterectomy | 1 | 2021 | 22 | 0.050 |
Why?
|
Naphthoquinones | 1 | 2021 | 5 | 0.050 |
Why?
|
Benzofurans | 1 | 2021 | 6 | 0.050 |
Why?
|
Aniline Compounds | 1 | 2021 | 31 | 0.050 |
Why?
|
Sulfonamides | 1 | 2021 | 40 | 0.050 |
Why?
|
Cost Savings | 1 | 2020 | 36 | 0.040 |
Why?
|
Quality Improvement | 1 | 2022 | 132 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2020 | 124 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 341 | 0.040 |
Why?
|
Mitotane | 1 | 2019 | 3 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2020 | 81 | 0.040 |
Why?
|
Disease-Free Survival | 1 | 2019 | 152 | 0.040 |
Why?
|
Blood Coagulation Disorders | 1 | 2019 | 16 | 0.040 |
Why?
|
Serum Albumin | 1 | 2019 | 19 | 0.040 |
Why?
|
Adolescent | 2 | 2020 | 2076 | 0.040 |
Why?
|
Operative Time | 1 | 2019 | 83 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 222 | 0.040 |
Why?
|
Anticoagulants | 1 | 2019 | 88 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 325 | 0.040 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 15 | 0.040 |
Why?
|
Portal Pressure | 1 | 2017 | 5 | 0.040 |
Why?
|
Hyperplasia | 1 | 2017 | 17 | 0.030 |
Why?
|
Mice | 1 | 2021 | 1345 | 0.030 |
Why?
|
Brain | 1 | 2006 | 1560 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2016 | 11 | 0.030 |
Why?
|
Models, Animal | 1 | 2016 | 110 | 0.030 |
Why?
|
Policy | 1 | 2015 | 7 | 0.030 |
Why?
|
Chicago | 1 | 2018 | 869 | 0.030 |
Why?
|
Smoking Cessation | 1 | 2015 | 41 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 618 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2018 | 340 | 0.030 |
Why?
|
Stents | 1 | 2015 | 80 | 0.030 |
Why?
|
Thrombocytopenia | 1 | 2014 | 20 | 0.030 |
Why?
|
Smoking | 1 | 2015 | 165 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2014 | 56 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2015 | 146 | 0.030 |
Why?
|
Lymphocyte Culture Test, Mixed | 1 | 2013 | 4 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2013 | 4 | 0.030 |
Why?
|
Immunity, Cellular | 1 | 2013 | 29 | 0.030 |
Why?
|
Cohort Studies | 1 | 2018 | 1781 | 0.030 |
Why?
|
Biomarkers | 1 | 2014 | 554 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2020 | 4459 | 0.020 |
Why?
|
Biocompatible Materials | 1 | 2011 | 88 | 0.020 |
Why?
|
Surveys and Questionnaires | 1 | 2015 | 1077 | 0.020 |
Why?
|
Hepatocytes | 1 | 2010 | 11 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2010 | 49 | 0.020 |
Why?
|
Angiography | 1 | 2009 | 29 | 0.020 |
Why?
|
Factor VIII | 1 | 2008 | 26 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2008 | 52 | 0.020 |
Why?
|
Hemorrhage | 1 | 2008 | 75 | 0.020 |
Why?
|
Hepatitis C, Chronic | 1 | 2008 | 37 | 0.020 |
Why?
|
Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 1 | 0.020 |
Why?
|
Histocompatibility Testing | 1 | 2008 | 2 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2008 | 3 | 0.020 |
Why?
|
Granzymes | 1 | 2008 | 5 | 0.020 |
Why?
|
Transplantation Conditioning | 1 | 2008 | 31 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2008 | 88 | 0.020 |
Why?
|
Laparoscopy | 1 | 2009 | 170 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2008 | 284 | 0.020 |
Why?
|
Transplantation, Homologous | 1 | 2008 | 248 | 0.020 |
Why?
|
Prospective Studies | 1 | 2011 | 1633 | 0.020 |
Why?
|
Vena Cava, Inferior | 1 | 2006 | 10 | 0.020 |
Why?
|
Syndrome | 1 | 2005 | 69 | 0.010 |
Why?
|
Biliary Tract | 1 | 2004 | 3 | 0.010 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 1 | 2004 | 4 | 0.010 |
Why?
|
Hepatic Artery | 1 | 2004 | 3 | 0.010 |
Why?
|
Magnetic Resonance Angiography | 1 | 2004 | 28 | 0.010 |
Why?
|
Preoperative Care | 1 | 2004 | 116 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2004 | 217 | 0.010 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2002 | 4 | 0.010 |
Why?
|
Forecasting | 1 | 2001 | 92 | 0.010 |
Why?
|